Aditxt, Inc. (NASDAQ:ADTX – Get Free Report) major shareholder Financial Lp Hrt sold 3,132,480 shares of the firm’s stock in a transaction on Tuesday, June 16th. The shares were sold at an average price of $0.01, for a total value of $31,324.80. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Large shareholders that own at least 10% of a company’s stock are required to disclose their transactions with the SEC.
Financial Lp Hrt also recently made the following trade(s):
- On Friday, June 12th, Financial Lp Hrt purchased 4,252,767 shares of Aditxt stock. The shares were bought at an average price of $0.02 per share, for a total transaction of $85,055.34.
- On Friday, June 5th, Financial Lp Hrt sold 735,462 shares of Aditxt stock. The stock was sold at an average price of $0.06, for a total transaction of $44,127.72.
- On Thursday, June 4th, Financial Lp Hrt acquired 843,622 shares of Aditxt stock. The shares were bought at an average cost of $0.08 per share, for a total transaction of $67,489.76.
- On Friday, April 24th, Financial Lp Hrt sold 1,089 shares of Aditxt stock. The shares were sold at an average price of $7.56, for a total transaction of $8,232.84.
- On Thursday, April 23rd, Financial Lp Hrt sold 141 shares of Aditxt stock. The stock was sold at an average price of $7.83, for a total transaction of $1,104.03.
- On Tuesday, April 21st, Financial Lp Hrt bought 2,700 shares of Aditxt stock. The stock was bought at an average cost of $8.91 per share, with a total value of $24,057.00.
- On Wednesday, April 22nd, Financial Lp Hrt sold 443 shares of Aditxt stock. The stock was sold at an average price of $8.10, for a total transaction of $3,588.30.
Aditxt Price Performance
ADTX opened at $0.01 on Friday. Aditxt, Inc. has a one year low of $0.00 and a one year high of $53,451.08. The company’s 50 day simple moving average is $3.71 and its 200-day simple moving average is $125.11. The stock has a market capitalization of $8,528.00, a P/E ratio of -0.00 and a beta of 0.84.
Analyst Upgrades and Downgrades
A number of equities research analysts have recently weighed in on the company. Weiss Ratings restated a “sell (e+)” rating on shares of Aditxt in a research report on Monday, April 20th. Wall Street Zen upgraded Aditxt to a “sell” rating in a report on Saturday, May 23rd. One analyst has rated the stock with a Sell rating, Based on data from MarketBeat, the stock currently has a consensus rating of “Sell”.
Check Out Our Latest Analysis on Aditxt
Aditxt Company Profile
Aditxt, Inc is a clinical-stage biotechnology company focused on the development and commercialization of natural antimicrobial peptides and microbiome-based detection technologies. Leveraging proprietary peptide libraries, the company aims to provide novel solutions for infection prevention and control across healthcare, food safety, animal health and agricultural markets. Aditxt’s approach centers on harnessing peptides that can disrupt microbial cell membranes without promoting resistance, addressing a growing need for alternatives to traditional antibiotics and chemical disinfectants.
The company’s product offerings include contract-based microbial detection and identification services, designed to help hospitals, food processors and other regulated industries monitor contamination levels and validate hygiene protocols.
Recommended Stories
- Five stocks we like better than Aditxt
- Aehr Spikes on New Order, But Has Stock Gotten Ahead of Itself?
- Rackspace’s AI Land Grab: Plugging Into the Next Compute Boom
- Satellogic Is Tiny But Its Revenue Growth Is Hard to Ignore
- Why Kroger’s Pullback Could Be a Gift for Patient Investors
Receive News & Ratings for Aditxt Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aditxt and related companies with MarketBeat.com's FREE daily email newsletter.
